Catalyst Pharmaceuticals (CPRX) Return on Capital Employed (2011 - 2026)

Catalyst Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 26.94% for Q1 2026.

• Quarterly Return on Capital Employed fell 316.0% year-over-year to 26.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26.94% (down 316.0% YoY) and the FY2025 annual result came in at 31.04%, down 509.0% from the prior year.
• Return on Capital Employed was 26.94% for Q1 2026 at Catalyst Pharmaceuticals, down from 27.7% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 37.05% in Q2 2023 and bottomed at 14.7% in Q2 2024.
• A 5-year average of 27.81% and a median of 28.24% in 2024 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 2235 bps — and 2025, when it jumped 1472 bps.
• Catalyst Pharmaceuticals' Return on Capital Employed stood at 34.31% in 2022, then plunged by 31 bps to 23.75% in 2023, then grew by 19 bps to 28.24% in 2024, then dropped by 2 bps to 27.7% in 2025, then retreated by 3 bps to 26.94% in 2026.
• Business Quant data shows CPRX's Return on Capital Employed at 26.94% in Q1 2026, 27.7% in Q4 2025, and 29.31% in Q3 2025.